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This 5-year prospective study of ophthalmologic find-
ings in 1299 patients treated with oral 8-methoxypso-
ralen photochemotherapy (PUV A) for psoriasis failed to 
demonstrate a significant dose-dependent increase in 
t he risk of developing symptomatic cataracts. These 
patients were instructed to _wear UV A-~locking eye-
glasses when exposed to sunlight and dunng treatment 
for a 12-h period beginning from the time of 8-methoxy-
psoralen ingestion . However, we did observe a small 
increase in the risk for development of nuclear sclerosis 
and posterior subcapsula1· opacities among patients who 
received at least 100 PUVA treatments, compared to 
patients with fewer than 100 treatments (relative risk 
= 2.3 and 3 .0, respectively; p < .05 both comparisons) . 
We compared our resu lts to those of a large, population-
based study and found, after adjusting for differences in 
methods, that the prevalence of cataracts in our study 
patients, aged 52-75 years, was not significantly differ-
ent. Since the latency period for development of symp-
tomatic ocular abnormalities may be longer than 5 
years, continued surveillance of our cohort and contin-
ued use of appropriate ocular protection by all patients 
treated with PUV A is indicated. 
The efficacv of ora l 8- methoxypso ra len a nd long- wave ultra-
violet rad iati~n ( UV A), kn own a!' PUVA , was first described in 
1974 as a treatment for pso ri asis [ 1]. Since the Food and Drug 
Adm inist ra tion approved PUVA therapy for treatment of se-
vere pso rias is in 1982. it s use in the nit.ed Sta tes a nd Europe 
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has increased. The PUVA follow-up tudy was organ ized in 
1975- 1976 as a 16-center prospective cohort study of t he long-
term safety and efficacy of PUV A therapy. Patients were ad-
vised to use UV A-blocking eyeglasses for 12 h following pso-
ralen ingestion if they were exposed to UV A from sun or 
a rtificial li ght sources. Physicians carin g for t hese patients 
periodically rem inded t hem of the impo rta nce of wearing pro-
tective eyeglasses. Ophthalmologic examinatio ns were per-
formed be fore the first t reatment a nd at regu lar in tervals 
thereafter. Data from these exam inations, as well as t he num-
bers of PUV A treatments, demographic cha racteristics, and 
pre- P UV A exposu res to other agents, including ora l corticoste-
roids, have permitted us to assess t he incidence and prevalence 
of ocu la r ab norm a li t ies a mong a defined cohort of PUV A-
treated patients. 
Psoralens have been found in huma n and anima l lenses after 
parenteral adm inist ration [2], a nd are known to photobind 
with lens proteins in the presence ofUVA radiation [3,4). High 
doses of' PUV A damage t he lens and other ocular structures in 
some a nima l spec ies [5- 7]. Although t he extent and reversibil -
ity of damage appears to vary with the dose a nd a mong a nima l 
spec ies, pe rmanent cataracts have been noted in some experi-
ments [8]. In human beings, psoralens remain in the lens for 
at least 12 h after ingestion [9J. Exposure to sufficient environ-
mental UV A during t hat t ime can lead to photoproducts that 
may remain in the lens fort he lifetime of t he patient. Although 
pat ients are instructed to wear UVA-blocking eyeglasses after 
pso ralen ingestion , t heir complia nce cannot be assured. Pre-
sumptive PUV A-induced cataracts have been reported in pa-
t ients who did not wear adequate eye protection after psoralen 
ingestion [10] . Ultrav iolet s lit lamp densitographic data on a 
se ries of patients t reated with PUVA indicated a significan t 
elevation in a lens f1uoresence peak t hat may be due to psoralen 
binding in the lens [10]. Thus , accelera ted cataract develop-
ment or othe r c ha nges in the lenses of patients treated with 
PUVA is a n important conce rn . Our findi ngs from an average 
of 5 years of prospective study suggest t hat exposure to PUV A 
therapy may be assoc iated with a sma ll increase in the ris k of 
lens abnormalities, but t hat a substantia l or s ignifican t increase 
in t he risk of symptomatic ocula r changes has not been detected 
in our large co hort of patients with long-term exposure to 
PUVA. 
MATERIALS AND METHODS 
/Jefi n it.ions 
We calcu lated the initial prevalence of each abnorma l ophthalmo-
log-ic finding- or int erest. as reco rded on the first comprehensive opht hal-
mologic examination. Patients with an ini t ially normal eye examination 
who had an abnorm al it~· on their fin al eye exam inat ion were considered 
to be incident cases. Final prevalence was based on abnormal findings 
I' rom each p:Hient's last op hthalmologic examinal ion. We defined nor-
mal visual acui ty as 20/ 25 or better. For compa rison tot he Framingham 
Study, we present our dat a using both 20/25 and 20/35 or bett er at 
normal. as detailed below Ill]. 
Lenses were defined as normal if' I he ophthalmologist did not detect 
on exam ination through a dilated pupil cortical, nuclear, posterior 
subcapsular. or ot her abnormalities considered by the investigat or t.o 
be "significant.'' Flecks (punctuate cortical opac ities) were not consid-
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e red lens abnorma liti es. S pace was provided on the eye examina tion 
form (Fig I ) fo r spec ifica ti on of the pa rti cula r type of abnorma lit y 
noted. 
For t he purpose of th is s tudy, patients we re de fin ed as hav ing a 
ca tm·aCL only if they had a bnorma l visua l acuity a nd a lens abno rm a li ty 
in one or both eves. We used thi s crit eri a because minor lens a bnor-
ma lities a ppea r LO he frequent. a nd the ir gradin g va ries ove r time and 
a mong exa mine rs. In th e few cases of patients with mul t ip le eye 
abno rma li t ies th at could have been respons ibl e for dec reased visua l 
acuity, a de finit e assessme nt of which a bnorma lity was respons ible was 
not poss ible clue to t he des ign of the ophtha lmology exa minat ion fo rm. 
Patient s with abnorma l visua l acuit y who had both le nticula r and other 
eye abnorma liti es a re descr ibed below. 
In addition to a nalyz ing ou r data for lens a bno rma li t ies a nd cata-
racts, we used free tex t nota tions on the eye exa minatio n fo rm to 
calcula te the incidence a nd preva lence of nuclea r sc leros is (NS) , a nd 
poster ior subcapsular ca ta rac ts. S i nee "pos terio r subcapsu la r ca ta racts" 
a re defined o n th e has is of le ns exa min at ion , independent of a patient 's 
visua l acuity, we d istingui sh this findin g from our diagnos is of "cata -
ract," by subseq ue ntly referr in g to "posterior subcapsula r cata rac t" as 
"poste rior subcapsula r opacity" ( PSO). S ince our NS a nd PSO data 
we re co llected from free tex t rat he r tha n from forced responses (i .e. , 
yes , no), we believe th at our es timates of t he preva lence a nd inc idence 
of these findin gs may be lower tha n result s from studies in which these 
findin gs a re recorded as forced respo nses. 
Study Popu la tion 
All 1380 pat ients who we re first t rea ted with PUVA from 1975- 1976 
a t i.6 unive rsit y ce nte rs as pa rt o r t.h e ora l methoxsalen photochell'o-
Lherapy clinical cooperat ive tri a l were eligibl e !"or entry inlO a pro~pec ­
ti ve f"o llow- up sLUdy [1 2[. Of t hese 1:380 patie nt s, 1299 had lens exa m-
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inations reco rded. These pat ie nt s were a n ave rage age of 44 yea rs at 
entry to the study, a nd 65 % were male. The studv met hodo loQV a nd 
co hort cha racter istics have bee n previous ly deta iled [1 3 [. b. 
According to the PUVA fo llow-up study protocol, each pat ient had 
an ophtha lmologic examinat ion performed a t t he time PUVA t reat-
ment was ini t iated, a nd a ll patients who cont inued PUVA therapy were 
advi sed to have repeat examinat ions pe rfo rmed at least annually. 
Patients no longe r active ly using PUVA were advised to have opht ha l-
mologic examin ations a t least a nnua lly for the fi rst 3 yea rs of follow-
up , a nd subsequently in a lte rnate yea rs. or 1380 pat ie nts , the 81 who 
lacked a ny op ht ha lmologic examinatio n had rela tively li ttle P UVA 
ex posure. Less t han one-fourth of this group had received more than 
50 PUVA treatments, compared to a mea n ex posure of more t ha n 120 
t reatments for t he 1299 pat ients wit.h a le ns examin ation. The e 1299 
pat ients were included in the ca lculat ion of preva lence of op htha lmo· 
logic ab norm a li t ies (see T ables I, II , a nd IV). We calculated incidence 
us ing Les ke's method [14 [. 
or t he 1299 pa t ients, on ly the 1037 patients (80 %) wit h a t. least 3 
opht ha lmologic exams recorded on the revised form (desc ribed below) 
were included as cases or co ntrols in our a na lys is of the relat ionship of 
PUVA dose to lens abno rmality developmen t. The ave rage t ime from 
first treatment to fin a l eye examin ation in thi s group of 1037 was 5.3 
yea rs, compa red to 3.5 yea rs fo r patients with fewe r t ha n 3 such 
exa minations. The I at te r group were more ofte n male (70 % vs 63 %, p 
< .05, chi squa re test), were younge r (mean age 42 vs 44 , p < .01 /-
test), a nd had fewe r P UV A trea tments (mean 70 vs 1:33, p < .01 , t- test) 
t han patients who had completed at least 3 eye exa minat ions on the 
rev ised form. 
Ophthalmologic Examination Forms and Examiners 
A brief op ht ha lmologic examination form was used prior to August, 
1976. Th is fo rm reco rded visua l acuity and intraocu la r pressure, and 
included space for a free tex t summ a ry of slit lamp a nd fundus exami-
nation results. A rev ised ophthalmologic exam inat ion form was in t ro-
duced in August , 1976 (Fig l ), an average o f 10 months a fter first 
treatment wit h PUVA. The rev ised form recorded t he findings of the 
ophtha lmologic examinat ion in a se t format , with free tex t space 
prov ided for spec ific assessment of abnorma lities oft he pupil s, lenses, 
di scs, and fundi , and ex pla nat ions o f crite ri a for t hese a bnorma lities. 
Although patients were not required to return to the same opht hal-
mologist for subsequent exa mina tions, mos t of the 16 cooperating 
centers t ried to have a s ingle ophthalmologist or a sma ll group of 
oph tha lmologists, who were fa milia r with potentia l P UVA eye compl i· 
cations, examine pat ients . 
Comparison to Population V ata 
We compared the age-spec ific prevalence o f abnorma l visua l acuity 
a nd le ns a bno rma lities for patients, as reco rded on t he ir fina l exami-
nation, with the preva lence calcu lated for the Fra mingham Eye S tudy 
Ill], in wh ich comprehens ive sta ndardized ophtha lmological exami-
nati ons were completed fo r 26:31 persons aged 52- 85 yea rs who were, 
or had been, reside nts of Framin gha m, Massachusetts. Afte r discuss ion 
with the principa l in vestigato r of the Fra mingha m St udy (personal 
communicatio n, Dr. Howa rd M. Leibowitz) , we dete rmined that, on 
average, we could expect as much as a on e line difference between t heir 
methods for measuring visua l acuity a nd met hods used in clinical 
practice, which a re compa ra ble t.o ours. For ex ample, a patie nt with a 
best corrected vi ua l acuity of 20/40 as measured by our study would 
likely have a measurement. of 20/30 if exa min ed by t he F ra mingham 
study. This diffe rence refl ects t he Framingham Study's rigo rous ex-
amination protocol, which included substa nt ia l efforts to have each 
pat ient achieve the best possible "best corrected visual acuit-y." \~1e 
t herefore made a one line adjustment in our data fo r compa ri sons with 
the Framingham da ta on cataracts a nd vi sua l acui ty . 
Relation of Ocular Abnormalities to Number of PUVA Treatments 
We exa mined t he relation of P UVA dose to t he incidence of cata-
racts, nuclea r sc leros is, posterior subcapsular cata racts, a nd opac ities. 
PUVA exposures were sp li t in to two ca tegories: (1) fewe r t ha n 100 
treatments; a nd (2) 100 or more treatments. A matc hed analys is was 
performed to control for co nfounding va ri ables in our a nalysis of 
incident cata racts. Cases were matched wit h controls from the same 
treatment center who had no lens abnorma li ty, had a t least 3 eye 
exa minat ions on the rev ised form , a nd were t he sa me sex a nd age 
(with in 5 yea rs) . 
Sept. 1985 OCULAR FINDINGS IN PATIENTS TREATED WITH PUVA 271 
RESULTS 
Incidence and Prevalence of Lens Abnormality 
Both t he prevalence and incidence of lens abnormality in-
creased with age (Table 1). Patients were classified according 
to their age at t he study's midpoint . Initia l prevalence of 
abnormal lens findings was less t han 10% for patients less than 
52 years old, and final prevalence was essentially unchanged 5 
years later. The prevalence of lens abnormalities increased from 
66% to 72% fo r patients 75 years of age and older. There were 
no significant differences in t he initial or final prevalence or 
incidence of lens abnormalities between men and women. A 
majority of patients over 65 years had some lens abnormality 
noted on their final examinat ion. 
Cataracts 
There was a total of 62 patients (4.8%) with cataracts when 
t hey entered t he study. These patients had lens abnormalities 
and best visual acuity of 20/30 or worse in one or both eyes on 
first and last examinations. By our criteria, a total of 60 new 
patients (4.6%) developed cataracts during the study. Three of 
these 60 patients had macular or corneal abnormalities that, 
along with lens opacities, may have been responsible for their 
v isual acuity decrease. Other abnormalities recorded for these 
3 patients in addition to t heir lens opacities were macular 
pigment atrophy, Fuch's dystrophy of the cornea with minimal 
senile atrophy, and macular drusen with pigment elevation of 
t he retina. Thirty-five patients who developed cataracts ac -
cording to our definit ion had entered t he study with normal 
lenses and normal visual acuity. The other 25 had one or more 
lens abnormalities, but had normal visual acuity on t heir first 
eye examination. There were 11 patients with abnormal visual 
acuity and lens findin gs when first examined, but with normal 
lenses on final examination. These patients are not counted as 
cataract patients in the fin al prevalence. After 5 years of follow-
up, the net increase in the number of patients with cataracts 
in our study group of 1299 patients was 49 (3.7%). Both the 
prevalence and incidence of cataracts increased with age (Table 
II) . The incidence of cataracts in patients 52 years of age and 
older was more t han 8 t imes t hat of pat ients under 52. 
Nuclear Sclerosis and Posterior Subcapsular Opacity 
Overall, t he proportion of patients with NS or PSO (recorded 
as lens abnormali t ies independent of visual acui ty abnormali-
ties) was comparable among study patients who entered wit h 
cataracts and patients who developed cataracts after P UV A 
exposure (Table III). Among patients who had normal lenses 
and visual acui ty before PUV A t reatment and developed cata-
racts, the proportion with NS was s light ly but not significantly 
higher (p > .2, chi square) than t he proportion among patients 
with cataracts detected on first examination (T able III) . 
Co mparison to Framingham Study Population 
The Framingham Study a lso demonstrated an age- related 
increase in lens abnorm ali t ies [11] . For compa rison with t his 
TABLE l. Prevalence of lens abnormality (per 100 patients) 
Age" Number of Initia l Final patients prevalence prevalenceh 
551 718 10 9 
52- 64 374 23 26 
65- 74 160 37 48 
?.75 47 66 72 
All ages 1299 19 21 
---
a Age at t hird (of 5) annual fo llow-up int erview. 
b Excludes 80 patients with lens abnormality reco rded on first ex-
ami nation on t he revised form, but lacking lens abnormality on last 
examination. Of t hese 80 patient s, 60 had lens abnormalit ies descri bed 
as "early," "small," "slight," " mild ,·' "minimal,·' "not a cataract,·' 
" flecks," or "spicules." 
TABLE II. P revalence of cataracts: lens abnormality and abnormal 
visual acuity= 20/30 or worse (per 100 patients) 
Age" Number of Initial Final Incidence patients prevalence prevalenceb per year 
551 718 0.4 1 0.2 
52- 64 374 5 8 0.6 
65- 74 160 14 29 3.2 
?.75 47 40 53 4.8 
All ages 1299 4 9 0.8 
• Age at t hird (of 5) annual follow-up interview. 
b Excludes 11 patients with abnormal lens examinations and visual 
acuity on first examination and normal lens examinations on final 
examination. 
TABLE III. Percentage of cataract patients with nuclear sclerosis (NS) 
and/or posterior subcapsular opacity (PSO) 
Numbers of 
Percentage 
with 
patients 
Prevalent cataract casesa 
Incident cataract casesb 
a. With lens abnormali ty 
before PUVA 
b. Wi t h neit her lens nor visual 
acui ty abnomality before 
PUVA 
51 
25 
35 
NS PSO 
33 29 
35 46 
46 31 
• Cataract present on ini tial and final eye examinations. 
b Patients with lens abnormality and visual acuity of 20/30 on final 
examination who did not have a cataract on first examination. 
TABLE IV. Prevalence of cataracts in. the PUVA and Framingham 
Study populations by age• (rate per 100 patients) 
Age" 
52- 64 
65-74 
?.74 
PUVA Study 
Prevalence of cataracts 
With cri teria for With cri teria for 
visual acuity visual acuity 
20/30 or worse 20/ 40 or worse 
7 4 
23 16 
59 57 
Framingham Study 
Prevalence of cataracts 
4 
13 
41 
• This represents t he patients' ages at fi na l examination. T he prev-
alences in this tab le are lower than in Tables I and II which used age 
at midpoin t to categorize patients. 
cohort, we grouped our patients according to t heir age at final 
examination rather than their age at the study's midpoint. 
Therefore, t he prevalence of cataracts in each age group is 
slight ly higher on T able IV t ha n on Tables I and II. The final 
prevalence of cata racts for patients over 52 years of age in the 
PUV A study, with visual acuity 20/30 or worse and lens abnor-
malities in each age group, was higher than in t he Framingham 
study (p < .01, a ll comparisons, chi square test) (Table IV). 
Howeve r, if we had used a visual acuity of 20/40 as our criteria 
for defining cataracts fo r t he PUV A cohort, as suggested by the 
director of t he Framingham Study, t he prevalence of cataracts 
in t he PUV A and Framingham cohorts would not be signifi -
cant ly diffe rent for patients under 75 years of age (p > .2 both 
comparisons, chi square test) (Table IV) . PUVA patients over 
74 years had a slightly higher prevalence of cataracts t han the 
Framingham patients (p < .05 , chi square test). 
Relation to Exposures 
The risk fo r developing NS was 2.3 t imes greater among our 
cohort patients who were exposed to 100 or more PUV A treat-
ments than among patients exposed to fewer t han 100 treat-
ments (95% confidence interval = 1.0-4.9). PSO was a lso 
diagnosed more frequently among patients who had received 
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TABLE V. Prevalence of other findings noted on ophthalmologic 
examination (per 100 patients) 
Initial Final 
prevalence preva lence 
External eye abnormality 3 9 
Anterior chamber 0.4 1 
EOM balance 1 2 
Corneal abnormality 5 5 
Media abnormality 1 3 
Fundus (any abnormality) 5 7 
Fundus specific findings: 
Sca r 1 3 
Nevus 1 1 
Aneurysms 1 1 
Hemorrhages 1 2 
Exudates 1 2 
100 or more PUVA treatments (relative risk = 3.0; 95% confi-
dence interval 1.1- 7.0). 
A matched analysis comparing each incident cataract case (a 
patient who developed a cataract) to a control (a patient who 
did not develop a cataract) from the same center, of the same 
sex, and within 5 years of age, showed no significant relation 
between level of PUVA exposure (low = fewer than 100 treat-
ments vs high = 100 or more treatments) and the risk of 
developing a cataract. When we separately considered patients 
who had a lens abnormality with normal visual acuity on their 
first examination and who developed a cataract, we found that 
the risk for cataract development was lower in patients with 
high PUV A exposure (relative risk = 0.3; 95% confidence 
intervals= 0.3- 4.2). In contrast, we observed a trend toward a 
slightly higher risk for cataract development in patients with 
initially normal lens examinations who had received high num-
bers of PUV A treatments (relative risk = 1.6; 95% confidence 
interval = 0.7-3.5) . Prior oral steroid use was significantly 
associated with the risk of PSO at entry to the study (relative 
risk= 2.2; 95 % confidence interval= 1.1- 4.7). Only 3 patients 
who developed PSO during the study had recorded their expo-
sure to oral steroids. No significant relation was noted between 
incident cases of PSO and past oral steroid use (p > .2 chi 
square test). 
Other Eye Findings 
The PUV A study ophthalmologic examination assessed all 
principal ocular structures as well as internal and external 
ocular function. Although lens changes are the principal theo-
retical ocular risk of PUVA therapy, this paper presents data 
on all the ocular structures studied. The initial and final prev-
alences of other eye findings were low, with the exception of 
external eye abnormalities such as blepharitis and ectropion 
which we expect to be frequent in patients with psoriasis (Tab!~ 
V) . 
One patient developed an eye tumor. A choroidal melanoma 
was noted in the left eye of a 55-year-old man, 7 years after his 
first PUV A treatment. The patient had received a total of 127 
PUV A treatments before the tumor developed. Diagnosis was 
based on ophthalmologic examination, color photos, ultra-
sound, and fluorescein angiogram. The consulting ophthalmol-
ogist did not believe that this case was suitable for P-32 
measurement and laser coagulation of the tumor was per-
formed. Three ophthalmologic examinations, performed 4 and 
6 years earlier, were normal. The only abnormalities that this 
patient had were a few small , scattered, pigmented scars, noted 
during an ophthalmologic examination 3 years before the tumor 
developed. 
DISCUSSION 
~he PUV A follow-up study has used periodic ocular exami-
natiOns for 5 years to assess the ophthalmologic changes that 
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have occurred in a large cohort of patients with psoriasis who 
were treated at 16 university centers. Our findings fail to 
demonstrate a significant relation between the number of 
PUV A exposures and an increased risk of symptomatic cata-
racts. We did note a modest but significant relation between 
high numbers of PUV A treatments and an increased risk in 
the. dev~lop~~nt of len.s c?anges that were not severe enough 
to 1mpa1T v1s10n. The mc1dence of eye abnormalities not in-
volving the lens or external ocular structures was low and the 
etiologic relation of the development of a choroidal ~elanoma 
to PUV A exposure in a single patient cannot be established. 
A previous study suggests that patients with psoriasis are not 
at higher risk for developing cataracts than are persons without 
this disease, independent of exposure to PUVA [15]. Other 
su;veys failed to detect any suggestion of eye damage in patients 
usmg 8-methoxypsoralen, but the number of patients assessed 
wa~ small. Back et al examined 13 patients 2-12 years after 
the1r first treatment with 8-methoxypsoralen for vitiligo and 
failed to detect any eye damage [16]. Ronnerfalt et al foll~wed 
46 patients for up to 5 years and did not believe that the eye 
changes they noted were due to PUVA exposure [17]. Ham-
mershoy and Jessen also failed to detect an increased cataract 
risk in their studies of 96 patients treated with PUVA (18] . 
The slightly higher risk for development of NS, or PSO and 
cataracts among patients exposed to PUV A doses and with 
initially normal lens examinations, supports our concern that 
PUV A exposure may slightly increase the risk of cataract 
f?rmation, even .among patients instructed to use eye protec-
tion. These findmgs cannot prove a relation between PUV A 
exp~sure and an increased risk of eye damage, but both our 
findings and the case reports of patients treated with PUV A 
who did not wear adequate eye protection and who developed 
cataract~ should reinforce our concerns about the possible 
?cular nsks of psoralen ingestion [10,19]. Our findings also 
illustr~te that larg~ numbers of patients and prolonged follow-
up p~nods are requ1red to demonstrate a statistically significant 
relat1on between an exposure and an infrequent adverse event 
the risk of which may be only slightly increased. ' 
. The apparent .association between PUV A exposure and the 
nsk for developmg NS, PSO, or a cataract in persons with 
i~itially normal lenses may reflect the effect of other therapeu-
tiC exposures, or patient characteristics associated with PUV A 
use and cataract risk. PUV A use and the use of other psoriasis 
tre~tments before starting PUV A treatment was highest among 
patients who had the greatest extent of psoriasis at entry to 
the PUVA study. Patients who developed a cataract after 
PUV A exposure tended to have more severe psoriasis involve-
ment. However, the extent of psoriasis among patients who had 
cataracts at the time they began PUV A treatment was not 
significantly greater than patients without cataracts at the time 
of entry into the study. This suggests that extent of psoriasis 
and exposure to therapies other than PUV A are not likely 
expla~ations for .the possible relation of high PUV A exposure 
t? th~ mcrease~ nsk of developing an eye abnormality. Observer 
b1as 1s a more hkely explanation for the weak relation between 
PUV A exposure and the risk for the development of a lens 
abnormality. While no attempt was made to inform the 
ophth~lmologist about the patient's exposure history, ophthal-
mologists who were aware that patients had been exposed to 
h1gh numbers of PUV A treatments may have graded borderline 
cha.nges as abnormal more frequently than when they examined 
patients whom they believed had relatively small numbers of 
PUV A treatments. 
A number of caveats should be noted in the interpretation of 
our data and comparison of our findings with those of the 
Framingham Study. While standardized forms were used mul -
tiple ophthalmologists examined our patients. These exa~ina­
tions were performed in physician offices and clinics rather 
th.an s~ecial ~acilities designed and staffed to conduct epide-
miOlogic stud1es. Interobserver and temporal differences in the 
Sept. 1985 OCULAR FINDINGS IN PATIENTS TREATED WITH PUVA 273 
recording of "mild" qualitative changes may account for the 
relatively high number of patients who had lens abnormalities 
noted on first , but not final examination. This finding points 
out the difficulty in determining the incidence of "mild" quali -
tative abnormalities. Substantial clinical changes are likely to 
be subject to Jess interobserver variability than mild changes. 
Therefore, we have great confidence in the reliability of our 
findings concerning more seve re changes, such as symptomatic 
cataracts. 
While we detect on ly a slight trend toward a relation between 
higher numbers of PUV A exposures and an increased risk for 
developing lens abnormal ities, varying patient compliance with 
t he use of protective eyeglasses may mask a dose- risk relation 
between the development of cataracts and increased exposure 
to PUV A. It seems likely that patients who undergo regular 
treatments are more frequently reminded to use protective 
eyeglasses, and are more likely to adhere to these directions 
than are patients who are t reated infrequently. If this is the 
case, patients who infrequently use PUV A migh t receive higher 
doses of PUV A to their lenses per t reatment. 
Our data, based on more than 6500 person-years of prospec-
tive study, suggest that, after 5 years and with adequate eye 
protection, PUVA therapy is accompanied by, at most, a small 
risk of eye damage. Since we do not know the latency period 
nor the threshhold for PUV A damage to the eye, we believe 
t hat our cohort warrants continued monitoring for possible 
ocular complications. The necessity of wearing adequate eye 
protection for at least 12 h after psoralen ingestion should 
continue to be stressed to patients (20]. 
We a re indebted to Marie Brigham, Rudee Lange, Debbie Cia ri , Pat 
McClelland, Luz Leal, Hildega rd Jorgensen , Carolyn Petersen , Pam 
Muzio, Charlotte Lee, Mariella Ferna ndez, Teri Olivier, Connie Hefflin , 
Diane Brass, Glenda Johnson, Lillian Freije, Sandra McNeil , Monroe 
G riffin, and Joan Clark, whose efforts made th is study possible, and to 
Gerry LeJeune for assistance with the manuscript. 
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